Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.69 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.59 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051323 | 0.96 | OPRM1 (0.68) | OPRM1OPRD1LTA4HERAP1ERAP2 | |
| SCHEMBL30052764 | 0.95 | KDM4E (0.62) | OPRM1OPRD1ERAP2ALOX15ACE | |
| SCHEMBL30307613 | 0.94 | OPRD1 (0.75) | OPRM1OPRD1LTA4HERAP1ERAP2 | |
| SCHEMBL30128516 | 0.93 | OPRD1 (0.73) | OPRM1OPRD1LTA4HERAP1ERAP2 | |
| SCHEMBL31038379 | 0.93 | OPRM1 (0.66) | OPRM1OPRD1LTA4HERAP1ERAP2 | |
| SCHEMBL30502977 | 0.92 | OPRD1 (0.69) | OPRM1OPRD1LTA4HERAP1ERAP2 | |
| SCHEMBL30502988 | 0.91 | OPRM1 (0.64) | OPRM1OPRD1LTA4HACE | |
| SCHEMBL31106415 | 0.91 | OPRD1 (0.73) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30605164 | 0.91 | ACE (0.59) | OPRM1OPRD1ERAP2ALOX15ACE | |
| SCHEMBL30503003 | 0.90 | OPRD1 (0.68) | OPRM1OPRD1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930743-A | ACE (angiotensin converting enzyme) inhibitory peptide, preparation method and application | 美泰科技（青岛）股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-121779489-A | Bioactive peptide in tobacco stems, screening preparation thereof and application of bioactive peptide in tobacco stems in resisting tobacco mosaic virus | 云南省烟草公司玉溪市公司 | 2026-04-03 | — | — | CN | disclosed |
| CN-119930743-A | ACE (angiotensin converting enzyme) inhibitory peptide, preparation method and application | 美泰科技（青岛）股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930743-A | ACE (angiotensin converting enzyme) inhibitory peptide, preparation method and application | 美泰科技（青岛）股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | OPRM1 804/4885OPRD1 402/4885LTA4H 3533/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | OPRM1 2130/4885OPRD1 2937/4885LTA4H 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.